Fluicell AB (publ)
Research Fluicell AB (publ) (5J90) on Bullrun: market cap EUR 3.56M, P/E 0.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker5J90
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 3.56M
- P/E0.0
- Financial periodQ1 2026
- RevenueSEK 6.09M
- Net incomeSEK 3.31M
- Free cash flow-SEK 984.00K
- Gross margin116.8%
Valuation Snapshot
latest market cap is EUR 3.56M; P/E is 0.0.
Peer valuation comparison
Latest P/E is 0.04x versus a Healthcare sector median of 24.46x (99.8% below).
Latest P/E is 0.04x versus a Sweden median of 18.57x (99.8% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 6.00M | -SEK 8.33M | -SEK 13.66M | 218.8% | -6.07 | SEK 2.26M | n/a | SEK 10.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 3.56M | 0.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Fluicell AB (publ)
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fluicell AB (publ)'s market cap?
Fluicell AB (publ)'s market capitalization is EUR 3.56M.
What is Fluicell AB (publ)'s P/E ratio?
Fluicell AB (publ)'s price-to-earnings (P/E) ratio is 0.0.
What does Fluicell AB (publ) do?
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration.